MTVA
Price
$0.79
Change
-$0.09 (-10.23%)
Updated
May 23 closing price
Capitalization
15.45M
NRXS
Price
$3.03
Change
-$0.17 (-5.31%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
23.09M
Interact to see
Advertisement

MTVA vs NRXS

Header iconMTVA vs NRXS Comparison
Open Charts MTVA vs NRXSBanner chart's image
MetaVia
Price$0.79
Change-$0.09 (-10.23%)
Volume$336.07K
Capitalization15.45M
Neuraxis
Price$3.03
Change-$0.17 (-5.31%)
Volume$159
Capitalization23.09M
MTVA vs NRXS Comparison Chart
Loading...
MTVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NRXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MTVA vs. NRXS commentary
May 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MTVA is a StrongBuy and NRXS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 26, 2025
Stock price -- (MTVA: $0.79 vs. NRXS: $3.20)
Brand notoriety: MTVA and NRXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MTVA: 39% vs. NRXS: 144%
Market capitalization -- MTVA: $15.45M vs. NRXS: $23.09M
MTVA [@Biotechnology] is valued at $15.45M. NRXS’s [@Biotechnology] market capitalization is $23.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $297.63B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MTVA’s FA Score shows that 0 FA rating(s) are green whileNRXS’s FA Score has 0 green FA rating(s).

  • MTVA’s FA Score: 0 green, 5 red.
  • NRXS’s FA Score: 0 green, 5 red.
According to our system of comparison, both MTVA and NRXS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MTVA’s TA Score shows that 4 TA indicator(s) are bullish while NRXS’s TA Score has 5 bullish TA indicator(s).

  • MTVA’s TA Score: 4 bullish, 3 bearish.
  • NRXS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MTVA is a better buy in the short-term than NRXS.

Price Growth

MTVA (@Biotechnology) experienced а +15.38% price change this week, while NRXS (@Biotechnology) price change was +42.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

MTVA is expected to report earnings on Mar 20, 2025.

NRXS is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NRXS($23.1M) has a higher market cap than MTVA($15.5M). NRXS YTD gains are higher at: 36.170 vs. MTVA (-61.094). NRXS has higher annual earnings (EBITDA): -8.02M vs. MTVA (-25.46M). MTVA has more cash in the bank: 21.7M vs. NRXS (261K). MTVA has less debt than NRXS: MTVA (154K) vs NRXS (477K). NRXS has higher revenues than MTVA: NRXS (2.46M) vs MTVA (0).
MTVANRXSMTVA / NRXS
Capitalization15.5M23.1M67%
EBITDA-25.46M-8.02M317%
Gain YTD-61.09436.170-169%
P/E RatioN/AN/A-
Revenue02.46M-
Total Cash21.7M261K8,314%
Total Debt154K477K32%
FUNDAMENTALS RATINGS
MTVA: Fundamental Ratings
MTVA
OUTLOOK RATING
1..100
2
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
93
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MTVANRXS
RSI
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 5 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 5 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 5 days ago
78%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 6 days ago
82%
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 5 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 5 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
MTVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NRXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CAISX10.960.11
+1.01%
Calamos International Small Cap Gr A
WSMRX24.890.06
+0.24%
William Blair Small-Mid Cap Growth R6
HIGJX19.84-0.04
-0.20%
Carillon Eagle Growth & Income I
PWJBX32.87-0.21
-0.63%
PGIM Jennison International Opps R2
MEFOX59.08-0.52
-0.87%
Meehan Focus

MTVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, MTVA has been loosely correlated with HOOK. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MTVA jumps, then HOOK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MTVA
1D Price
Change %
MTVA100%
-9.79%
HOOK - MTVA
44%
Loosely correlated
-6.79%
PMVP - MTVA
35%
Loosely correlated
+0.51%
KPRX - MTVA
30%
Poorly correlated
-0.35%
MCRB - MTVA
30%
Poorly correlated
+3.09%
IMTX - MTVA
28%
Poorly correlated
-1.73%
More

NRXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NRXS has been loosely correlated with CVM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if NRXS jumps, then CVM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRXS
1D Price
Change %
NRXS100%
N/A
CVM - NRXS
58%
Loosely correlated
+2.03%
CTMX - NRXS
25%
Poorly correlated
+4.69%
NGNE - NRXS
24%
Poorly correlated
-4.21%
ALT - NRXS
24%
Poorly correlated
-1.04%
TCRT - NRXS
23%
Poorly correlated
+4.72%
More